101 related articles for article (PubMed ID: 21504445)
1. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
Lazar J; Poonawalla T; Teng JM
Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
[TBL] [Abstract][Full Text] [Related]
3. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
[No Abstract] [Full Text] [Related]
4. [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].
Martínez C
Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():69-71. PubMed ID: 21381292
[TBL] [Abstract][Full Text] [Related]
5. A Pediatric Case of Sclerodermatous Graft-Versus-Host Disease Responsive to Ultraviolet A1 Phototherapy.
Lazzeri L; Tripo L; Pescitelli L; Ricceri F; Prignano F
Pediatr Dermatol; 2016; 33(2):e99-102. PubMed ID: 26871550
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
Distler JH; Distler O
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
8. Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
[TBL] [Abstract][Full Text] [Related]
9. Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
Kim H; Kim NH; Kang HJ; Lee JW; Kim MS; Park KD; Shin HY; Ahn HS
Pediatr Transplant; 2012 Dec; 16(8):910-2. PubMed ID: 23050745
[No Abstract] [Full Text] [Related]
10. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Kim YJ; Kim DW; Lee S; Kim YL; Hwang JY; Park YH; Kim HJ; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2004 Jan; 33(2):237-42. PubMed ID: 14628081
[TBL] [Abstract][Full Text] [Related]
12. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
Bibi Y; Gottlieb AB
J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
[TBL] [Abstract][Full Text] [Related]
13. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation.
Schaich M; Schäkel K; Illmer T; Ehninger G; Bornhäuser M
Ann Hematol; 2003 May; 82(5):303-4. PubMed ID: 12707720
[TBL] [Abstract][Full Text] [Related]
14. Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?
Papadakis V; Karakasis D; Sfikakis PP; Baltadakis I; Apostolidis J; Evangelou K; Gorgoulis VG; Harhalakis N
Leuk Lymphoma; 2009 Mar; 50(3):471-4. PubMed ID: 19253137
[No Abstract] [Full Text] [Related]
15. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
16. Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy.
Brandon JA; Jennings CD; Kaplan AM; Bryson JS
J Immunol; 2011 Mar; 186(6):3726-34. PubMed ID: 21296982
[TBL] [Abstract][Full Text] [Related]
17. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
Skert C; Patriarca F; Sperotto A; Cerno M; Filì C; Zaja F; Stocchi R; Geromin A; Damiani D; Fanin R
Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
[TBL] [Abstract][Full Text] [Related]
18. Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease.
Wolff D; Reichenberger F; Steiner B; Kahl C; Leithäuser M; Skibbe T; Friedrich T; Terpe H; Helbig W; Freund M
Bone Marrow Transplant; 2002 Feb; 29(4):357-60. PubMed ID: 11896434
[TBL] [Abstract][Full Text] [Related]
19. A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy.
Gebhardt C; Averbeck M; Paasch U; Ugurel S; Kurzen H; Stumpp P; Simon JC; Treudler R
Arch Dermatol; 2009 May; 145(5):571-4. PubMed ID: 19451502
[TBL] [Abstract][Full Text] [Related]
20. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
